COVAX vaccine programme to deliver 237 mn doses to 142 nations by end-May

The timeline for the delivery of doses, made by AstraZeneca and by India's Serum Institute, will be split into separate two-month schedules, COVAX said in a statement

vaccine, vaccination, coronavirus, covid
COVAX is the programme backed by the World Health Organization and GAVI vaccine alliance to provide vaccines for poor and middle-income countries
Reuters
2 min read Last Updated : Mar 02 2021 | 8:40 PM IST
The COVAX vaccine-sharing programme said on Tuesday it will deliver 237 million doses of AstraZeneca's Covid-19 shot to 142 countries by the end of May as it steps up the global roll-out of its vaccine supplies.
 
The timeline for the delivery of doses, made by AstraZeneca and by India's Serum Institute, will be split into separate two-month schedules, COVAX said in a statement, with the first in February-March and the second in April-May.
 
"These timelines are dependent on a variety of factors including national regulatory requirements, availability of supply, and fulfillment of other criteria such as validated national deployment and vaccination plans," the statement said.
 
COVAX is the programme backed by the World Health Organization and GAVI vaccine alliance to provide vaccines for poor and middle-income countries. It began its roll-out last week with the first deliveries of shots to Ghana and Ivory Coast.
 
"It can't be overemphasized enough that we are undertaking the largest and most complex vaccine rollout in history," Seth Berkley, GAVI chief executive officer, told a news conference.
 
"We are just starting, but we should see more and more countries being served in coming weeks and months including those at all income levels and across the world," he said.
 
Hailing the campaign as an "unprecedented partnership", WHO Director-General Tedros Adhanom Ghebreyesus said Angola, Cambodia, Democratic Republic of Congo and Nigeria could also expect deliveries of COVAX-supplied vaccines on Tuesday.
 
"This is an unprecedented partnership that will not only change the course of the pandemic but also change the way the world responds to future health emergencies," Tedros said.
 
Ghanaian President Nana Akufo-Addo told the same briefing that his West African country, which this week began its inoculation campaign with COVAX doses, aimed to vaccinate 20 million people by the end of 2021.
 
The COVAX statement said that as well as the first round of allocations of the AstraZeneca vaccine, some 1.2 million doses of the Pfizer-BioNTech shot were also anticipated for delivery in the first quarter of 2021.
 
COVAX hoped to finalise a deal with Novavax for 1.1 billion doses in coming weeks, Berkley said.
 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineAstraZenecaSerum Institute of IndiaWorld Health Organization

Next Story